



## CORRIGENDUM

## Golimumab in radiographic and nonradiographic axial spondyloarthritis: a review of clinical trials [Corrigendum]

Toussiro E, Vauchy C, Binda D, Michel F. *Drug Des Devel Ther.* 2016;10:2087–2094.

On page 2089, a column heading in Table 1 was incorrectly presented. The last column heading was presented as “Golimumab 60 mg”, whereas this should have been presented as “Golimumab 100 mg” as shown below:

**Table 1** Proportion of ASAS20 responders in the GO-RAISE and GO-AHEAD studies

Study	Placebo	Golimumab 50 mg	Golimumab 100 mg
GO-RAISE, primary end point at Week 14 <sup>15</sup>	21.8	59.4	60
GO-RAISE, 2 years <sup>17</sup>	38.5	60.1	71.4
GO-AHEAD, primary end point at Week 16 <sup>16</sup>	40	71.1	NA

**Abbreviations:** ASAS, Assessment of SpondyloArthritis international Society; NA, not available.

## Drug Design, Development and Therapy

## Dovepress

### Publish your work in this journal

Drug Design, Development and Therapy is an international, peer-reviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are the features of the journal, which

has also been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <http://www.dovepress.com/drug-design-development-and-therapy-journal>